| 摘要 |
Therapeutic efficacy of monoclonal antibodies can be enhanced by using plasma derived, polyclonal immune serum globulin as a vehicle for the monoclonal antibodies. Enhanced protective activity is demonstrated by using a combination of monoclonal antibodies specific to Pseudomonas aeruginosa in a plasma derived immune serum globulin (ISG), preferably an ISG having a high titer of plasma derived polyclonal antibodies to P. aeruginosa. |
